编者按:慢性淋巴细胞白血病(CLL)是以B淋巴细胞为主的淋巴细胞增殖性疾病,临床预后具有显著的异质性。随着细胞生物学、细胞免疫学及分子遗传学的进展,CLL预后指标除了年龄、疾病分期(Rai/Biet分期)、外周血淋巴细胞计数、免疫表型等,还增加了细胞遗传学异常及其他血清学标志物,此外也涌现出一系列新型药物用于CLL的治疗。在刚结束的美国血液学会(ASH)年会上,组委会特别设计了“How I Treat: Bringing Science to Clinical Dilemmas”这一环节,针对CLL在基础与临床的研究进展进行了探讨。会后,《肿瘤瞭望》记者专访了主讲嘉宾、美国国立卫生研究院贝塞斯达国家心肺与血液研究所Adrian Wiestner教授。
Video Player is loading.
Current Time 0:00
Duration 0:00
Remaining Time -0:00
This is a modal window.
The media could not be loaded, either because the server or network failed or because the format is not supported.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
美国国立卫生研究院贝塞斯达国家心肺与血液研究所 Adrian Wiestner教授访谈
《肿瘤瞭望》:影响CLL预后的重要因素?
Prof. Wiestner: The most important factor is to separate Ig-mutated from Ig-unmutated CLL. This refers to sequences that encode the B-cell receptor. Surprisingly, it was found that CLL has both types, mutated and unmutated. This is part of the maturation process of B-cells and is something that is irreversible. Mutated in this regard is positive in the sense that they are more mature B-cells. These patients do better than those with Ig-unmutated cells. So that separates two important groups. The other important marker can be assessed by flow cytometry and that is CD49d expression.
Wiestner教授:影响CLL预后最重要的因素在于免疫球蛋白重链(IgVH)的突变状态,即编码B细胞受体的基因序列是否突变。可以将CLL分为突变型CLL(M-CLL)与未突变型CLL(U- CLL)。前者疾病进展快,生存期短;后者疾病进展慢,预后也较好。在某种层面上讲,IgVH突变具有积极的意义,这意味着有更多的成熟B细胞,患者的预后情况也更好。因此,IgVH突变是目前区别CLL预后的重要因素。此外,应用流式细胞技术评估CD49d的表达也被作为一项重要的预后指标。
《肿瘤瞭望》:CLL细胞遗传学的研究进展?
Prof. Wiestner: It may not be a single genetic event. One of the risk factors is a 17p deletion. One of the risk factors is a complex karyotype. One of the risk factors is NOTCH1 mutations in certain types of B-cell receptor specificities. There is a very elegant paper from Dr Ferreira’s group that does gene sequencing and they have identified some candidate mutations.
Wiestner 教授:CLL的发生发展过程并不是单一的遗传学改变,而是一系列复杂的基因改变的结果。其中,染色体 17P的缺失、复杂核型、B细胞受体特异型NOTCH1基因突变等都属于CLL的遗传学危险因素。目前,Ferreira博士的研究团队通过基因测序已确定了部分突变候选基因,这项研究成果有着的重大意义。